Blue Earth Diagnostics
With the acquisition of prostate cancer imaging specialist Blue Earth Diagnostics, Bracco Imaging enriched its product portfolio with high-standard oncology nuclear imaging solutions that allow us to address the most pressing issues facing cancer treatment and care facilities around the world.Learn more
Blue Earth Therapeutics
Robust patient care
Blue Earth Therapeutics (BET) is dedicated to developing and delivering the next generation of precision-targeted, therapeutic radiopharmaceuticals for the treatment of cancer patients. BET's mission is to go beyond the frontiers of cancer treatment and drive real results for clinicians and patients worldwide.Learn more
Centro Diagnostico Italiano
The value of quality healthcare
An important area of activity of the Bracco Group is the stellar healthcare services provided by the Centro Diagnostico Italiano (CDI). CDI is a Milan-based polyclinic specialized in different services of prevention, diagnosis, rehabilitation, and personalized treatment – with a focus on radiosurgery and the very latest technological advancements at its disposal.Find out more
E-Z-EM Canada Inc
Built in 1998 and subsequently expanded in 2000 and 2004, the plant has been certified by the Canadian, United States and European health authorities (Health Canada, FDA, EMEA). Supported by a solid Health, Safety and Environment program, the team at E-Z-EM Canada manufactures contrast media in an ISO14001 certified facility and is proud to export quality products all over the world.Learn more
Enhancing the surgeon's vision
In October 2017, Bracco acquired SurgVision, a high-tech innovative start-up company specialized in developing a real-time Fluorescence Image Guided Surgery platform combining a targeted imaging agent and a device for efficient tumor visualization during oncology surgical procedures.
As surgery remains the primary curative option for most solid cancers, a predominant challenge for surgeons during these procedures has been the limitations of visual inspection and digital palpation to distinguish tumors from healthy tissue. Fluorescence Image Guided Surgery represents an innovative intra-operative optical technique aimed at assisting surgeons in distinguishing tumors from surrounding tissue, using a combined infrared camera and contrast agent approach. In this context, SurgVision’s innovative targeting solution is expected to provide significant improvements versus competing modalities and products, due to the extremely advanced features of its optical camera and the very sensitive targeting performance of its new imaging agent.
It's the company's mission to:
- provide researchers and clinicians with a custom-designed optical imaging camera system that allows a smooth transition from clinical research to routine applications
- develop integrated optical imaging platforms, including camera, software, and target-specific tracer(s), for specific disease areas like breast-conserving surgery, peritoneal carcinomatosis, and esophageal cancer
SurgVision was founded in August 2013, as a spin-off of the Technical University of Munich and it is headquartered in Groningen, The Netherlands, with a development team in Munich, Germany.
No company can prosper without
Across all Bracco business properties, corporate responsibility is key to operation. Internally and externally. We believe that responsible behaviour and business success are inseparable. That it's critical to safeguard the confidence and trust of our partners and customers as well as our dedicated employees.How we act responsibly
Because people deserve
At Bracco, we have a long and strong entrepreneurial tradition of developing clinically important products and related services to support healthcare professionals optimize their diagnostic procedures. And we are on a continuous path to innovation, addressing unmet medical needs, and improving production processes efficiency.
The application of artificial intelligence (AI) and machine learning techniques is advancing rapidly. And the potential of these to improve precision, risk assessment, and overall efficiency in diagnostic imaging is impressive. Our ambition is to take pole position and dominate the race in the "intelligent imaging" revolution.
Our long-term commitment to innovation and improvement is not a business strategy. It's why we get up in the morning.